Boston Scientific Corp (NYSE:BSX), a global medical technology leader, develops, manufactures, and markets a broad range of medical devices used in various interventional medical specialties. The company offers products that are used in cardiology, endoscopy, urology, neuromodulation, and other fields.
According to a recent SEC filing, Wendy Carruthers, the Executive Vice President of Human Resources at Boston Scientific Corp, sold 6,983 shares of the company on March 1, 2024. The transaction was executed at an average price of $66.35 per share, resulting in a total value of $463,271.05.
Over the past year, the insider has sold a total of 130,677 shares of Boston Scientific Corp and has not made any purchases of the stock. The company's insider transaction history reveals a pattern of 38 insider sells and no insider buys over the same timeframe.
The market capitalization of Boston Scientific Corp stands at $98.93 billion, reflecting the scale of the company within the medical devices industry. The stock's price-earnings ratio is currently 63.02, which is above the industry median of 27.64. This valuation metric suggests a premium compared to the broader industry.
Boston Scientific Corp's shares were trading at $66.35 on the day of the insider's recent transaction. The stock's price relative to the GuruFocus Value (GF Value) of $54.18 indicates a price-to-GF-Value ratio of 1.22, categorizing the stock as modestly overvalued according to GuruFocus's valuation model.
The GF Value is determined by considering historical trading multiples, a GuruFocus adjustment factor based on the company's past performance, and future business performance estimates provided by Morningstar analysts.
Investors and analysts often monitor insider transactions as they can provide insights into a company's internal perspective on the stock's valuation and future prospects. Wendy Carruthers's recent sale may attract attention from the market as stakeholders evaluate the significance of this insider activity within the context of Boston Scientific Corp's current valuation and stock performance.
This article, generated by GuruFocus, is designed to provide general insights and is not tailored financial advice. Our commentary is rooted in historical data and analyst projections, utilizing an impartial methodology, and is not intended to serve as specific investment guidance. It does not formulate a recommendation to purchase or divest any stock and does not consider individual investment objectives or financial circumstances. Our objective is to deliver long-term, fundamental data-driven analysis. Be aware that our analysis might not incorporate the most recent, price-sensitive company announcements or qualitative information. GuruFocus holds no position in the stocks mentioned herein.
